

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

DIVISION OF CORPORATION FINANCE

July 30, 2018

Jeffrey G. Lamothe Chief Financial Officer Aptevo Therapeutics Inc. 2401 4th Avenue, Suite 1050 Seattle, Washington 98121

> Re: Aptevo Therapeutics Inc. Form 10-K for Fiscal Year Ended December 31, 2017 Filed March 13, 2018 File No. 001-37746

Dear Mr. Lamothe:

We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Division of Corporation Finance Office of Healthcare & Insurance